

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>
D	<input checked="" type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: **4 April 2011**

State Party to the Convention: **Republic of Lithuania**

Exchange of data on research centres and laboratories¹

1. Name(s) of facility²

National Public Health Surveillance Laboratory

2. Responsible public or private organization or company

Ministry of Health

3. Location and postal address

Zolyno Str. 36, LT-10210 Vilnius, Lithuania

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Ministry of Health

5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)

None

6. If no maximum containment unit, indicate highest level of protection

Level 2

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Personal and public health purposes: diagnosis of bacterial infectious diseases such as Anthrax, Tularaemia, Plague, Brucellosis, Cholera, Legionellosis, other Food- and Waterborne Diseases, Botulism, etc.

HIV, HTLV, enteroviruses and poliomyelitis, influenza and parainfluenza, measles, rubella, herpes infections, viral haemorrhagic fevers, parasitoses, tick born diseases, etc.

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

1. Name(s) of facility⁴

National Food and Veterinary Risk Assessment Institute

2. Responsible public or private organization or company

State Food and Veterinary Service

3. Location and postal address

J. Kairiukscio Str. 10, LT-08409 Vilnius, Lithuania

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

State Food and Veterinary Service

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

None

6. If no maximum containment unit, indicate highest level of protection

Level 3

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Rabies, Highly pathogenic avian influenza, Newcastle disease, Leptospirosis, Anthrax, Foot and mouth disease, Swine vesicular disease, Bluetongue, African horse sickness, African swine fever, Classical swine fever (hog cholera), Tuberculosis, Brucellosis, Salmonellosis, Listeriosis, Vibriosis, Campylobacteriosis, Yersiniosis, Shigellosis, Toxoplasmosis, Trichinellosis, and other viral, parasitical and bacterial diseases of animals

⁴For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

⁵In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Form A, part 2 (i)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

Form A, part 2 (ii)

National biological defence research and development programme

NSTR

Form A, part 2 (iii)

National biological defence research and development programme

NSTR

Form B (i)

Background information on outbreaks of reportable infectious diseases

This is in accordance with the WHO International Statistical Classification of Diseases and Related Health Problems, 10th Revision

Certain infectious and parasitic diseases in Lithuania for 2010

**WHO Classification of
Disease**

Case per year

(1) Human diseases (number of cases per year)

Diseases	2009	2010
AIDS	37	33
Amebiasis	16	23
Botulism	0	4
Brucellosis	1	0
Campylobacteriosis	706	884

Chancroid	0	0
Chicken-pox	12698	11042
Chlamydial infections	326	367
Cholera	0	0
Diphtheria	0	0
Giardiasis	13	20
Gonococcal infections	391	315
Gonococcal ophtalmia neonatorum	Is included into Gonococcal	Is included into Gonococcal
H.Influenzae B (invasive)	2	2
Hepatitis A	16	16
Hepatitis B	58	71
Hepatitis C	47	41
Hepatitis non A-non B	0	2
Hepatitis other unspecified virai	0	0
Legionellosis	0	1
Leprosy	0	0
Listeriosis	5	5
Malaria	3	3
Measles	0	2
Pneumococcal meningitis	9	10
Other bacterial meningitis	48	52
Viral meningitis	130	197
Meningococcal infections	65	50
Mumps	74	87
Paratyphoid	1	0
Pertussis	233	19
Plague	0	0
Poliomelitis	0	0
Rabies	0	0
Rubella	0	2
Congenital rubella	0	0
Salmonellosis	2069	1766
Shigellosis	37	42
Syphilis, Congenital	4	2
Syphilis, Early Latern	326	345
Other Syphilis	Is included into Syphilis, Early Latern	Is included into Syphilis, Early Latern
Tetanus	0	2
Trichinelosis	115	77
Tuberculosis	1057	986
Typhoid fever	0	0
Verotoxigenic E.coli infection 0157	0	2
Yellow Fever	0	0

Lithuania

Form B (i)

Background information on outbreaks of reportable infectious diseases

(2) Human diseases (outbreaks)

Diseases	2009 m.	2010 m.
Shigellosis	0	2
Salmonellosis	50	40
Trichinellosis	2	6
Staphylococcal infection (S. aureus)	2	No information
Tick-borne encephalities	0	0
Rotoviral infection	40	44
Not confirmed etiology	68	89

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

NSTR

Form C

Encouragement of publication of results and promotion of use of knowledge

NSTR

Form D

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

NSTR

2. Information regarding other opportunities

NSTR

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other Measures	Amended since last year
a) development, production, stockpiling, acquisition, or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
b) exports of micro-organisms* and toxins	YES	YES	YES	NO
c) imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.

10 April 1997

2. Past offensive biological research and development programmes:

- **NO**
- Period(s) of activities
- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:

- **NO**
- Period(s) of activities
- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Declaration of vaccine production facilities

No vaccines are produced in Lithuania